The TPC clinical track carries out clinical trials to rigorously test whether personalised treatment decisions based on biomarker panels improve the clinical outcome, compared to standard treatment. Depending on the resulting findings, predictions from data discovered in the Data Science track will be tested in new clinical trials.
TPC technologies have been applied to 241 tumor samples collected over three years and across three cancer indications:
– metastatic melanoma
– metastatic epithelial ovarian cancer
– acute myeloid leukemia (AML).
The selection of these indications was based on the potential clinical benefit and availability of sufficient tumor material for simultaneous analysis across all technologies.
In addition to multiple bulk approaches, an average of two million single cells per patient were profiled across six technologies with single-cell readouts.
An in-depth analysis of the data acquired at the cohort level, including the clinical outcome of each patient collected over a 6-month follow-up period, is performed in the context of an «Exploratory Science loop», in which the multiscale approach will be used to improve the understanding of the disease and discover novel biomarkers.
If you would like to learn more about the TPC's clinical studies, please contact us
You can support the work of the TPC with a donation through the ETH foundation.